英菲格拉替尼的副作用与注意事项

Infigratinib is a targeted therapy for patients with cholangiocarcinoma with abnormal FGFR2 genes. This article will introduce in detail the relevant information of Infigratinib from three aspects: side effects, precautions and efficacy, to help patients and doctors better understand the characteristics and use of this drug.

Side effects of Infigratinib

Infigratinib may cause a variety of side effects during treatment. Understanding these side effects can help patients prepare psychologically in advance and take timely response measures.

Common adverse reactions

Common adverse reactions of infigratinib include nail toxicity, stomatitis, dry eyes, fatigue, hair loss, etc. Although these symptoms are relatively common, in most cases they can be alleviated through symptomatic treatment or dose adjustment.

Laboratory Abnormalities

During treatment, patients may experience laboratory abnormalities such as increased serum creatinine, fluctuations in phosphate levels, and elevated ALT/AST. Changes in these indicators require regular monitoring so that treatment plans can be adjusted in a timely manner.

Serious adverse reactions

Retinal pigment epithelial detachment (RPED), hyperphosphatemia and soft tissue mineralization are serious adverse reactions of infigratinib. Patients need to undergo regular eye examinations and blood phosphorus monitoring, and if necessary, suspend or reduce drug dosage.

Understanding the types and manifestations of side effects can help patients cope more calmly during treatment, and can also better cooperate with doctors in monitoring and adjustments.

Precautions for Infigratinib

Special attention should be paid to some key matters when using Infigratinib.

Ophthalmic toxicity monitoring

Infigratinib may cause vision problems, so an eye examination is required before and every 3 months during treatment. If vision changes occur, seek immediate medical evaluation.

Hyperphosphatemia Management

Elevated serum phosphate levels are a common problem with infigratinib. When serum phosphorus exceeds 5.5 mg/dL, phosphate binders need to be used; when it exceeds 7.5 mg/dL, medication needs to be suspended.

Drug interactions

The combination of infigratinib and CYP3A inhibitors or inducers may affect the efficacy of the drug. In addition, gastric acid inhibitors (such as PPIs) will reduce drug absorption and should be avoided when used simultaneously.

Strictly following the precautions can effectively reduce treatment risks and improve the therapeutic effect of drugs.

The efficacy of Infigratinib

The efficacy of Infigratinib is mainly reflected in the treatment of patients with cholangiocarcinoma with abnormal FGFR2 genes, and its indications are based on accelerated approval.

Scope of Indications

Infigratinib is suitable for patients with unresectable locally advanced or metastatic cholangiocarcinoma confirmed by testing to have FGFR2 fusion or rearrangement. Its efficacy was evaluated by overall response rate (ORR) and duration of response (DoR).

Dose adjustment and efficacy

For patients with mild to moderate liver and kidney function impairment, the dose needs to be adjusted to 100 mg or 75 mg. Reasonable dosage adjustment can reduce adverse reactions while ensuring efficacy.

The treatment cycle of Infigratinib is 28 days. It is taken continuously for 21 days and then stopped for 7 days. This intermittent dosing method helps balance the efficacy and side effects.

Infigratinib provides a new treatment option for specific patients with cholangiocarcinoma, but its long-term efficacy still needs further verification.